Journey Medical Corp Announces New Journey with the Experts Video Featuring Stephanie Fabbro, MD

Dr. Fabbro discusses cutaneous T-cell lymphoma, a type of cancer with an incidence of approximately six cases per one million
 
SCOTTSDALE, Ariz. - April 8, 2022 - PRLog -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical") today released a new Journey with the Experts video featuring Stephanie Fabbro, MD, FAAD, a board-certified dermatologist with Buckeye Dermatology in Columbus, Ohio. Dr. Fabbro sits down with Journey Medical to discuss cutaneous T-cell lymphoma, including what it is, why it occurs and how those affected can seek treatment from their local dermatology practice.

According to the Leukemia & Lymphoma Society, cutaneous T-cell lymphoma is a type of cancer that begins in white blood cells called T lymphocytes (T cells). The accumulation of T cells in the skin leads to the formation of patches, plaques, or tumor nodules. To view the Journey with the Experts video featuring Dr. Fabbro, please visit https://vimeo.com/692385096/93de238b80.



About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

The information, including, without limitation, topics, presentations, discussions, content, descriptions or any other material contained herein is for informational purposes only. None of the material herein is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified HCP with any questions you may have regarding a medical condition or treatment and before undertaking a new healthcare regimen. Never disregard professional medical advice or delay seeking it because of something you have heard, observed, or inferred herein. Any reliance is strictly prohibited.

About Journey Medical Corporation

Journey Medical (NASDAQ:DERM) is a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company currently markets nine products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical, visit https://journeymedicalcorp.com/.

About Stephanie Fabbro, MD, FAAD

Dr. Fabbro is Core Faculty for the Riverside Methodist Hospital Dermatology Residency Program and a dermatologist at Buckeye Dermatology. Prior to joining the Riverside program, Dr. Fabbro was the Dermatology Director of the Multidisciplinary Cutaneous T-Cell Lymphoma Clinic at the James Cancer Center at the Ohio State University. Dr. Fabbro graduated from medical school at Northeast Ohio Medical University (NEOMED) in 2012 as part of the accelerated BS/MD program. She did her residency in dermatology and fellowship in clinical ethics at the Ohio State University where she finished post-graduate training in 2016. Her other interests include clinical bioethics and she was the author of multiple book chapters in the Dermatoethics textbook and specializes in dermatoethics consults. Dr. Fabbro is heavily involved at the state and national level with the Ohio Dermatologic Association, the Bioethics Network of Ohio, and the American Academy of Dermatology.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words "we", "us" and "our" may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees' and consultants' ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Media Contact
Jaclyn Jaffe and Bill Begien
Journey Medical Corporation
***@jmcderm.com
(781) 652-4500
End
Email:***@jmcderm.com Email Verified
Tags:Dermatology
Industry:Medical
Location:Scottsdale - Arizona - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share